MANGALAM DRUGS & ORGANICS LTD.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹104.75
- Today's High:
- ₹109
- Open Price:
- ₹107.55
- 52W Low:
- ₹95
- 52W High:
- ₹172.65
- Prev. Close:
- ₹107.5
- Volume:
- 16955
Company Statistics
- Market Cap.:
- ₹1.71 billion
- Book Value:
- 95.98
- Revenue TTM:
- ₹3.70 billion
- Operating Margin TTM:
- 3.93%
- Gross Profit TTM:
- ₹1.22 billion
- Profit Margin:
- 0.34%
- Return on Assets TTM:
- 2.64%
- Return on Equity TTM:
- 0.84%
Company Profile
MANGALAM DRUGS & ORGANICS LTD. had its IPO on under the ticker symbol MANGALAM.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. MANGALAM DRUGS & ORGANICS LTD. has a staff strength of 0 employees.
Stock update
Shares of MANGALAM DRUGS & ORGANICS LTD. opened at ₹107.55 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹104.75 - ₹109, and closed at ₹105.1.
This is a -2.23% slip from the previous day's closing price.
A total volume of 16,955 shares were traded at the close of the day’s session.
In the last one week, shares of MANGALAM DRUGS & ORGANICS LTD. have increased by +0.14%.
MANGALAM DRUGS & ORGANICS LTD.'s Key Ratios
MANGALAM DRUGS & ORGANICS LTD. has a market cap of ₹1.71 billion, indicating a price to book ratio of 1.4081 and a price to sales ratio of 0.4963.
In the last 12-months MANGALAM DRUGS & ORGANICS LTD.’s revenue was ₹3.70 billion with a gross profit of ₹1.22 billion and an EBITDA of ₹255.18 million. The EBITDA ratio measures MANGALAM DRUGS & ORGANICS LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, MANGALAM DRUGS & ORGANICS LTD.’s operating margin was 3.93% while its return on assets stood at 2.64% with a return of equity of 0.84%.
In Q1, MANGALAM DRUGS & ORGANICS LTD.’s quarterly earnings growth was a negative -89.4% while revenue growth was a negative 24.7%.
MANGALAM DRUGS & ORGANICS LTD.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 136.7722
- PEG
Its diluted EPS in the last 12-months stands at ₹0.79 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MANGALAM DRUGS & ORGANICS LTD.’s profitability.
MANGALAM DRUGS & ORGANICS LTD. stock is trading at a EV to sales ratio of 0.6668 and a EV to EBITDA ratio of 7.494. Its price to sales ratio in the trailing 12-months stood at 0.4963.
MANGALAM DRUGS & ORGANICS LTD. stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹19.90 billion
- Total Liabilities
- ₹7.79 billion
- Operating Cash Flow
- ₹-635866000.00
- Capital Expenditure
- ₹1.27 billion
- Dividend Payout Ratio
- 0%
MANGALAM DRUGS & ORGANICS LTD. ended 2024 with ₹19.90 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹19.90 billion while shareholder equity stood at ₹7.56 billion.
MANGALAM DRUGS & ORGANICS LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹7.79 billion in other current liabilities, 274973000.00 in common stock, ₹7.29 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹507.84 million and cash and short-term investments were ₹2.36 billion. The company’s total short-term debt was ₹3,206,284,000 while long-term debt stood at ₹2.91 billion.
MANGALAM DRUGS & ORGANICS LTD.’s total current assets stands at ₹6.69 billion while long-term investments were ₹0 and short-term investments were ₹931.80 million. Its net receivables were ₹369.98 million compared to accounts payable of ₹970.73 million and inventory worth ₹2.57 billion.
In 2024, MANGALAM DRUGS & ORGANICS LTD.'s operating cash flow was ₹-635866000.00 while its capital expenditure stood at ₹1.27 billion.
Comparatively, MANGALAM DRUGS & ORGANICS LTD. paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹105.1
- 52-Week High
- ₹172.65
- 52-Week Low
- ₹95
- Analyst Target Price
- ₹
MANGALAM DRUGS & ORGANICS LTD. stock is currently trading at ₹105.1 per share. It touched a 52-week high of ₹172.65 and a 52-week low of ₹172.65. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹106.84 and 200-day moving average was ₹114.6 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5173.8% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About MANGALAM DRUGS & ORGANICS LTD.
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates at VAPI in India and internationally. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atorvastatin Calcium, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base. In addition, it offers specialty chemicals, such as Menthol; 2,3-Dihydrophthalazine-1, 4-dione; and 4-cynoethyl-2-methyl phenol. The company was incorporated in 1972 and is based in Mumbai, India.